1,782,007 Shares in Ventyx Biosciences, Inc. (NASDAQ:VTYX) Purchased by Point72 Asset Management L.P.

Point72 Asset Management L.P. bought a new stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,782,007 shares of the company's stock, valued at approximately $3,903,000. Point72 Asset Management L.P. owned about 2.52% of Ventyx Biosciences as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Catalina Capital Group LLC purchased a new stake in shares of Ventyx Biosciences in the fourth quarter valued at about $25,000. AXQ Capital LP purchased a new position in Ventyx Biosciences during the fourth quarter worth about $29,000. Palumbo Wealth Management LLC raised its holdings in Ventyx Biosciences by 97.1% during the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock worth $52,000 after purchasing an additional 11,792 shares in the last quarter. MetLife Investment Management LLC raised its holdings in Ventyx Biosciences by 76.0% during the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after purchasing an additional 11,543 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in Ventyx Biosciences by 23.3% during the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock worth $90,000 after purchasing an additional 7,768 shares in the last quarter. 97.88% of the stock is owned by hedge funds and other institutional investors.

Ventyx Biosciences Stock Up 19.0%

NASDAQ VTYX traded up $0.29 during trading hours on Thursday, hitting $1.82. 7,994,068 shares of the stock were exchanged, compared to its average volume of 1,331,142. The company has a market cap of $129.51 million, a price-to-earnings ratio of -0.77 and a beta of 0.73. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $5.66. The stock has a 50-day moving average of $1.21 and a 200 day moving average of $1.74.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.09. On average, equities research analysts expect that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.